Avoid common mistakes on your manuscript.
Corrections to: Drugs & Therapy Perspectives (2020) 36:427–434 https://doi.org/10.1007/s40267-020-00771-5
The author has alerted us to the following errors, and the following corrections should be noted:
Page 431, ‘What is the tolerability profile of lemborexant?’ section, paragraph 2, lines 2–6: the following sentence, which previously read:
“Single and multiple doses of lemborexant 10 mg did not have any negative effects on the apnea-hypopoea index (a measure of OSA severity) or peripheral capillary oxygen saturation (a measure of respiratory function)”.
should read:
“Single and multiple doses of lemborexant 10 mg did not have any negative effects on the apnea-hypopnea index (a measure of OSA severity) or peripheral capillary oxygen saturation (a measure of respiratory function)”.
Page 433, reference list: Reference 12, which previously read:
12. Beuckmann CT, Ueno T, Nakagawa M, et al. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep. 2019;42(6).
should read:
12. Beuckmann CT, Ueno T, Nakagawa M, et al. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep. 2019;42(6):zsz076.
Page 433, reference list: Reference 13, which previously read:
13. Mahoney CE, Mochizuki T, Scammell TE. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. Sleep. 2019;43(6).
should read:
13. Mahoney CE, Mochizuki T, Scammell TE. Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. Sleep. 2019;43(6):zsz302.
Page 434, reference list: Reference 16, which previously read:
16. Moline M, et al. Effect of lemborexant compared with placebo and zolpidem extended release on sleep architecture in older adults with insomnia disorder [abstract]. Sleep Med. 2019;64(Suppl 1):s437.
should read:
16. Moline M, Pinner K, Cheng J, et al. Effect of lemborexant compared with placebo and zolpidem extended release on sleep architecture in older adults with insomnia disorder [abstract]. Sleep Med. 2019;64(Suppl 1):s437.
Page 434, reference list: Reference 29, which previously read:
29. Vermeeren A, Jongen S, Murphy P, et al. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep. 2019;42(4).
should read:
29. Vermeeren A, Jongen S, Murphy P, et al. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep. 2019;42(4):zsy260.
The original article has been updated.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Blair, H.A. Correction to: Lemborexant in insomnia disorder: a profile of its use. Drugs Ther Perspect 36, 598–599 (2020). https://doi.org/10.1007/s40267-020-00784-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-020-00784-0